SAREPTA THERAPEUTICS INC.
-
USD
(-)
- 15 min delayed data - NASDAQ Stocks
| Open: | - |
| Change: | - |
| Volume: | - |
| Low: | - |
| High: | - |
| High / Low range: | - |
| Type: | Stocks |
| Ticker: | SRPT |
| ISIN: |
SAREPTA THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
SAREPTA THERAPEUTICS INC. - More news...
SAREPTA THERAPEUTICS INC. - More news...
- 02/28/2025 - 14:00 Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program
- 02/26/2025 - 21:05 Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments
- 02/14/2025 - 13:30 Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility
- 02/12/2025 - 13:30 Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results
- 01/27/2025 - 06:00 Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS
- 01/13/2025 - 17:25 Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue
- 01/06/2025 - 13:30 Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- 12/31/2024 - 21:10 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 12/18/2024 - 13:30 Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
- 11/29/2024 - 21:10 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 05/29/2024 - 21:48 Sarepta Therapeutics Set to Join S&P MidCap 400
- 11/05/2023 - 02:09 ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
- 11/03/2023 - 17:50 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
- 08/02/2023 - 20:05 Sarepta Therapeutics Announces Second Quarter 2023 Financial Results and Recent Corporate Developments
- 07/31/2023 - 22:08 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 07/26/2023 - 12:30 Sarepta Therapeutics to Announce Second Quarter 2023 Financial Results
- 07/05/2023 - 12:30 Sarepta Therapeutics Announces Sale of Priority Review Voucher for $102 million
- 07/03/2023 - 12:30 Sarepta Therapeutics to Present at Cowen's 2nd Annual RNA Therapeutics Summit
- 06/30/2023 - 22:20 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 06/22/2023 - 18:02 Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy
- 05/31/2023 - 22:16 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 05/24/2023 - 12:00 Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001
- 05/12/2023 - 23:02 Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy
- 05/02/2023 - 20:05 Sarepta Therapeutics Announces First Quarter 2023 Financial Results and Recent Corporate Developments
- 04/28/2023 - 22:15 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 04/25/2023 - 12:30 Sarepta Therapeutics to Announce First Quarter 2023 Financial Results
- 04/13/2023 - 23:45 ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
- 04/10/2023 - 13:37 Sarepta Therapeutics Announces that the Date of the Advisory Committee Meeting for SRP-9001 will be May 12, 2023
- 04/06/2023 - 19:15 SRPT LOSS ALERT: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
- 04/03/2023 - 14:40 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
